Picture EBD Group World of Partnering Opportunities 650x100px
Financing › Details

Zetta Genomics–SEVERAL: investment, 202402 2nd seed financing round expansion by £1.8m to total of £3.7m


Period Period 2024-02-08
  Predecessor Zetta Genomics–SEVERAL: investment, 202304 2nd seed financing round £1.9m with led by Nina Capital
Organisations Money taker Zetta Genomics Ltd.
  Group Zetta Genomics (Group)
  Money source SEVERAL
Products Product XetaBase platform (genomic data management technology)
  Product 2 venture capital
Persons Person Warme, Louise (Werfen 202402 Head of We Venture Capital)
  Person 2 Subirats, Marc (Nina Capital 202202 General Partner)

Zetta Genomics Ltd.. (2/8/24). "Press Release: Zetta Genomics Expands Second Seed Funding Round with Additional £1.8 Million".

Zetta Genomics has expanded its second seed round, attracting new investment and growth expertise. With £6.2 million secured over two years, Zetta scales global operations and customer offerings to transform precision medicine and personalised healthcare.

Fast-scaling genomic data pioneer, Zetta Genomics, has expanded its second seed round – securing an additional £1.8 million and strengthening investor expertise. Demonstrating continued confidence from first-round VCs, the expansion also attracts fresh investment from diagnostics start-up specialist We Venture Capital, as Zetta Genomics – with its transformational XetaBase tertiary genomic data analysis platform – configures for Series A.

Zetta Genomics founder and CEO, Ignacio Medina, said, “Zetta Genomics is already making a difference to patients as XetaBase empowers clinicians to make faster and more accurate diagnoses at scale. With this extension to our second seed funding round now finalised, we are scaling and innovating our technologies, and enhancing customer focus.”

Investor confidence

Zetta Genomics’ latest funding sees fresh commitments from second-round global investors – some of the most innovative and successful healthtech VCs in the world: Nina Capital; Apex Ventures; and Cambridge Enterprise. New investment comes from We Venture – the innovation VC arm of global specialised diagnostics leader, Werfen. We Venture strengthens Zetta Genomics’ investor expertise with a focus on innovative diagnostic start-ups poised to transform markets.

Louise Warme, head of We Venture Capital says, “Zetta provides an incredibly powerful tool for analysis and data management in the quickly expanding NGS market. Increased speed and precision in analysis will support both patient outcome as well as workflow for the healthcare system and research. We are very impressed with the Zetta teams´ capacity and very much look forward to our collaboration going forward.”

Growth roadmap

The second seed funding extension precedes Series A, planned for late 2024, and allows Zetta Genomics to:

> encompass 500,000 genomes under management;

> configure customer success capabilities – to continue excellence in delivery while capturing and focusing on fast-evolving customer priorities;

> deepen bioinformatics and translation expertise;

> build out engineering capabilities to ensure a continuous cycle of innovation, development and delivery;

> Continue international growth, with an initial focus on the UK, US and Spain.

Marc Subirats, General Partner at Nina Capital, said, “Genomic-enabled predictive and precision medicine has the potential to deliver uniquely targeted research, therapeutics and care – driving radical improvements to both health outcomes and health economics. Zetta Genomics’ genomic data management and analytics technologies are ideally positioned to deliver on genomic potential.”

Configured for scale

The latest £1.8 million investment accelerates momentum and builds on Zetta Genomics’ £2.5 million first seed round finalised in February 2022 and £1.9 million in April 2023. Since then, Zetta Genomics has:

> expanded its footprint with new headquarters in Cambridge UK and offices in Valencia, Spain;

> built out strategic partnerships with industry leaders including Microsoft, Fujitsu and IQVIA.

Dr. Elaine Loukes, Investment Director at Cambridge University, said, “Zetta Genomics’ pioneering technologies – spun out from the University of Cambridge – are maturing to the point where they will make medical research more efficient, deliver ever more effective care – and make this care more affordable. Zetta Genomics’ technologies will power improved health outcomes for millions of people around the world.”

Record changed: 2024-02-21


Picture Demy-Colton BioFuture 2024 NYC Reimagine Healthcare 650x200px

More documents for Zetta Genomics (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture Demy-Colton BioFuture 2024 NYC Game Changers 650x300px

» top